[go: up one dir, main page]

PT1982178E - Métodos para o tratamento de distúrbios afectivos - Google Patents

Métodos para o tratamento de distúrbios afectivos

Info

Publication number
PT1982178E
PT1982178E PT77033272T PT07703327T PT1982178E PT 1982178 E PT1982178 E PT 1982178E PT 77033272 T PT77033272 T PT 77033272T PT 07703327 T PT07703327 T PT 07703327T PT 1982178 E PT1982178 E PT 1982178E
Authority
PT
Portugal
Prior art keywords
tmeff2
modulator
compound
treatment
methods
Prior art date
Application number
PT77033272T
Other languages
English (en)
Inventor
Marcelo Paez-Pereda
Marta Labeur
Original Assignee
Max Planck Gesellschaft
Phenoquest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Phenoquest Ag filed Critical Max Planck Gesellschaft
Publication of PT1982178E publication Critical patent/PT1982178E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/301Anxiety or phobic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/302Schizophrenia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/304Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT77033272T 2006-02-07 2007-02-07 Métodos para o tratamento de distúrbios afectivos PT1982178E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06002474 2006-02-07

Publications (1)

Publication Number Publication Date
PT1982178E true PT1982178E (pt) 2013-10-24

Family

ID=38066498

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77033272T PT1982178E (pt) 2006-02-07 2007-02-07 Métodos para o tratamento de distúrbios afectivos

Country Status (8)

Country Link
US (1) US8153127B2 (pt)
EP (1) EP1982178B1 (pt)
CY (1) CY1114523T1 (pt)
DK (1) DK1982178T3 (pt)
ES (1) ES2435793T3 (pt)
PL (1) PL1982178T3 (pt)
PT (1) PT1982178E (pt)
WO (1) WO2007090631A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835803B (zh) * 2007-10-19 2016-05-25 健泰科生物技术公司 半胱氨酸改造的抗tenb2抗体和抗体药物偶联物
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
IL296683B2 (en) 2014-01-21 2023-12-01 Neurocrine Biosciences Inc Preparations for the treatment of congenital adrenal hyperplasia
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN120284862A (zh) * 2018-12-07 2025-07-11 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
CN114711192B (zh) * 2022-04-13 2022-11-29 中国科学院西北高原生物研究所 一种长效抑郁症动物模型的构建试剂盒及构建方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
BRPI0510883B8 (pt) * 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação

Also Published As

Publication number Publication date
WO2007090631A1 (en) 2007-08-16
ES2435793T3 (es) 2013-12-23
CY1114523T1 (el) 2016-10-05
EP1982178A1 (en) 2008-10-22
DK1982178T3 (da) 2013-09-08
PL1982178T3 (pl) 2014-02-28
US8153127B2 (en) 2012-04-10
EP1982178B1 (en) 2013-07-24
US20100069463A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
PT1982178E (pt) Métodos para o tratamento de distúrbios afectivos
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
WO2008005469A3 (en) Igfbp2 biomarker
WO2009085209A3 (en) Methods for using and identifying modulators of delta-like 4
MX2009000914A (es) Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
EP2114241A4 (en) METHOD AND SYSTEM FOR PROVIDING ANALYTE MONITORING
WO2010011944A3 (en) Protein screeing methods
WO2008131224A3 (en) Diabetes-related biomarkers and methods of use thereof
MX2010005080A (es) Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
WO2009018511A3 (en) Alpha7 nachr agonists for treating or preventing metabolic disorders
WO2008137069A3 (en) Dental appliance wear indication and release agent receptacle
GB2502007A (en) Assay assembly and method
WO2007028110A3 (en) Methods for using and identifying modulators of delta-like 4
WO2006023966A3 (en) Assessment of cardiovascular risk
WO2008020942A3 (en) R-spondin compositions and methods of use thereof
PL2129391T3 (pl) Metoda diagnostyczna
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy
EP2350656A4 (en) METHOD AND KITS FOR IDENTIFYING INVASIVE GLIOBLASTOMES
WO2007092487A3 (en) Materials and methods for identifying agents that modulate norrin. norrin mimetics, and agents identified thereby
WO2009120801A3 (en) Ikki inhibitor therapies and screening methods, and related ikki diagnostics
WO2012006056A3 (en) Ccr6 as a biomarker of alzheimer's disease
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
DE102005023067A8 (de) Vorrichtung zur Prüfung der Dichtungsbelastbarkeit
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest